---
title: Improve thinking with brain stimulation
nct_id: NCT05919485
phase: NA
status: RECRUITING
sponsor: Istanbul Medipol University Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05919485"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05919485"
last_fetched: "2026-05-10T14:06:50.116Z"
source: "Parkinson's Pathways (curated)"
---
# Improve thinking with brain stimulation

**Goal (in five words):** Improve thinking with brain stimulation

**Official Title:** The Effects of Specific Transcranial Direct Current Stimulation tDCS on Cognition in Mild Cognitive Impairment: A Novel Study Protocol

**Trial ID:** [NCT05919485](https://clinicaltrials.gov/study/NCT05919485)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Istanbul Medipol University Hospital
- **Target Enrollment:** 120 participants
- **Start Date:** 2023-08-01
- **Completion Date:** 2023-12-30
- **Conditions:** Alzheimer Disease, Parkinson Disease
- **Interventions:** tDCS
- **Intervention Types:** PROCEDURE

## Summary For Families

The goal is to see whether gentle, noninvasive electrical stimulation of the scalp can improve memory and other thinking skills in people with mild cognitive impairment related to Parkinson's or early Alzheimer's. The approach uses transcranial direct current stimulation, a very low, painless current applied to targeted brain regions to boost neuronal activity involved in memory and attention, and it is given alongside participants' regular medications rather than replacing levodopa or other drugs. They are enrolling 120 literate adults aged 45 to 80, balanced by sex, who have Parkinson's with mild cognitive impairment or amnestic MCI, are on stable medications for at least one month, and who do not have dementia, major medical or other neurologic/psychiatric conditions, or any contraindication to tDCS or fMRI.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Providing an informed consent;
2. Literate and between 45-80 years of age;
3. 60 females and 60 males;
4. Diagnosed with PD based on criteria suggested by UK Parkinson's Disease Society, Brain Bank and PD-MCI in accordance with the diagnostic criteria suggestions by Litvan;
5. Diagnosed with aMCI based on diagnosis criteria (CDR\>0.5) suggested by Petersen;
6. On a stable pharmacological treatment minimum for one month with no washout period.

Exclusion Criteria:

* Illiterate or education level less than primary school
* Having an existing and/or prior neurological disease; psychiatric disease or head trauma; and/or irreversible hearing or sight problems or other medical illness (e.g. diabetes mellitus, hypertension);
* Exhibiting signs of dementia for PD group ;
* Having medical issues that prevent undergoing fMRI or for tDCS application.
```

## Locations (1)

- Alanya Alaaddin Keykubat Üniversitesi, Antalya, Alanya, Turkey (Türkiye) _(36.9081, 30.6956)_
  - Cennet Sena Parlatan, pHD Cand — (CONTACT) — 05077799164 — cennet.parlatan@std.medipol.edu.tr

## Central Contacts

- Burak Yuluğ, Prof. DR. MD — (CONTACT) — +90 242 510 6135 — burakyulug@gmail.com
- Cennet Sena Parlatan, PhD Cand — (CONTACT) — +90 507 779 91 64 — cennetsenaparlatan@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT05919485*  
*HTML version: https://parkinsonspathways.com/trial/NCT05919485*  
*Source data: https://clinicaltrials.gov/study/NCT05919485*